Sigyn Therapeutics (SIGY) Operating Leases (2021 - 2025)

Sigyn Therapeutics has disclosed Operating Leases across 5 years of filings, most recently posting $109800.0 for Q1 2025.

• In Q1 2025, Operating Leases fell 36.55% year-over-year to $109800.0; the TTM figure through Mar 2025 stood at $109800.0 (down 36.55% YoY), while the FY2024 annual figure was $56356.0, down 55.38% from the prior year.
• Operating Leases came in at $109800.0 for Q1 2025 at Sigyn Therapeutics, up from $56356.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $275928.0 in Q1 2022 to a low of $56356.0 in Q4 2024.
• Average Operating Leases over 5 years is $196675.0, with a median of $208303.0 recorded in 2023.
• Year-over-year, Operating Leases rose 1.11% in 2022 and plunged 55.38% in 2024.
• Over 5 years, Operating Leases stood at $240625.0 in 2021, then slipped by 22.11% to $187425.0 in 2022, then plunged by 32.61% to $126302.0 in 2023, then sank by 55.38% to $56356.0 in 2024, then jumped by 94.83% to $109800.0 in 2025.
• Per Business Quant data, the three most recent Operating Leases figures were $109800.0 in Q1 2025, $56356.0 in Q4 2024, and $142398.0 in Q3 2024.